PF-Atlas › Clinical Trials › NCT03727802
Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis
TRK-250 · Phase 1
Registry ID
NCT03727802
Phase
Phase 1
Status
Completed
Drug / intervention
TRK-250
Sponsor
Toray Industries, Inc
Start
2018-11-28
Enrollment
34
Locations
11
About this trial
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, at the gene expression level. This study is a double-blind, randomized, placebo-controlled Phase I study. The primary objective of the study is to assess the safety and tolerability of single and multiple inhaled doses of TRK-250 in subjects with idiopathic pulmonary fibrosis (IPF).
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03727802 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.